26th Annual ESGO 2025 Congress
Discover it Now!
The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure the fulfilment of its mission.
The Chair of the Prevention Committee is Prof. Murat Gultekin.
+ Over 30 panelists from all over the globe
+ Representatives of MEMAGO, PARSGO and BGICC
+ Understanding the magnitude of the disease (sharing local country stories)
+ Prevention (Marc Arbyn, Elmar Joura, Murat Gultekin, Patrick Petignat, and many others)
+ Colposcopy (Mihaela Grigore, Vesna Kesic, Kimon Chatzistamatiou, Mario Preti, and many others)
+ Risk-stratifies treatment (David Cibula, Maria Kyrgiou, Mohammed Ezzet Charfi, and many others)
ESGO Prevention committee invites you to join an important activity initiated via the European Cancer Organisation (ECO) - the European survey on HPV-related anogenital neoplasia service provision (ANNECA Survey).
Routine screening of women with the provision of treatment for cervical pre-cancer helps in the prevention of cervical cancer. However, this is not the case for the prevention of other anogenital cancers in women and men caused by the same HPV infection.
This survey aims to evaluate knowledge, attitudes, and current practices on managing HPV-related anogenital precancers across European countries to identify any future needs. Please enter your own experience regarding anogenital neoplasia management (not your organisation or guidelines). Thank you for taking the time to fill out this questionnaire. You can reach this Survey by using the link or QR code
Prevention Committee Chair: Murat Gultekin
Members:
Marc Arbyn, Utku Akgor, Esat Bilal, Nicolo Bizzarri, Sarah Bowden, Laia Bruni, Laura Burney Ellis, Murat Cengiz, Kimon Chatzistamatiou, Volkan Ege, Dimitrios Haidopulos, Houssein El Hajj, Nicolo Gallio, Omar Gassama, Livia Giordano, Charlotte Goutallier, Mihaela Grigore, Reda Hemida, Elmar Joura, Joana Kacperczyk-Bartnik, Vesna Kesic, Maria Kyrgiou, Belen Lopez, Edina Lukacs, Claudia Marchetti, Anita Mitra, Nagham Ibraheem Mahdi, Afraa Mahjoob Al-Naddawi, Gadelkareem Nassar, Eva-Maria Niine-Roolaht, Patrick Petignat, Alejandra Picconi, Mario Preti, Zoia Razumova, Jalid Sehouli, Aleksandra Shavrova, Nadja Taumberger, Charalampos Theofanakis, Icó Tóth, Andreas Ullrich, Zvi Vaknin, Alexandra Wagner, Ignacio Zapardiel
+ Pregnancy and HPV (Houssein El Hajj, France)
+ Colposcopy during pregnancy (Vesna Kesic, Serbia)
+ Prevention before and during pregnancy (Mihaela Grigore, Romania)
+ Screening in pregnant women (Marc Arbyn, Belgium)
Moderators: Laura Burney Ellis (UK), Zoia Razumova (Sweden)
Please register for this webinar here.
All Prevention Committee webinars are available on the eAcademy portal
Click on the link to see them all.
For recordings go to the ESGO eAcademy portal. You need to register to access it.
For recordings go to ESGO eAcademy portal. You need to register to access.
For recordings please go to the ENGAGe YouTube channel.
vulvar lesions, M. Preti, published as a joint publication in IJGC and LJGTD, June 2022
treatment for cervical intra-epithelial neoplasia and early invasive cervical cancer, M. Kyrgiou Accepted for publication in Lancet Oncology.
vulvar and vaginal disease, M. Preti (Accepted as joint publication in IJGC and LJGTD).
World Health Organization has launched ''Cervical Cancer Elimination Program'' on November 19, 2020.
The program asks the countries to vaccinate the girls under 15 years of age (90% coverage), to screen females by minimal two times when they are 35 and 45 (70%) coverage and to treat the lesions detected appropriately (in 90% of cases).
Modelling studies show that if all countries can implement the program until 2030 and can achieve these targets, there will be a 30% reduction in cervical cancer mortality by 2030 and the cervical cancer may be eliminated until the end of this century (namely incidence less than 4 \ 100.000).
ESGO Prevention committee has joined in to fulfil the WHO cervical cancer elimination strategy as a leading European actor in prevention.
RISCC: Risk-based Screening for Cervical Cancer
ESGO/ENGAGe is involved in the Horizon 2020 RISCC project.
Within the RISCC project ESGO / ENGAGe is responsible for the co-creation of the e-health/m-health platform for risk based cervical cancer screening and for the dissemination of the results to 12 ENGAGe member countries. This project is planned for five years and intended to terminate in 2025.
For more information about the ESGO/ENGAGe involvement please use the following link.
Dr. Murat Gultekin was awarded the IGCS Distinguished Advocacy Award for his extensive and tireless efforts to unify advocacy NGOs throughout Europe, forming ENGAGe. As the leading founder of HPV DNA Screening, Mobile Trucks and Central Mammography Report Unit, cancer registry systems and community- based palliative care system he is partly responsible for major innovations in cancer screening in Turkey and around the world. For more info visit the IGCS website.